New radiation approach aims to cut treatment time for rare cancer
NCT ID NCT06812052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a shorter, more intense radiation schedule for people with retroperitoneal sarcoma, a rare cancer in the abdomen. The main goal is to check safety and side effects like nausea and diarrhea within 30 days. Only 6 participants will be enrolled to see if this approach is tolerable before surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETROPERITONEAL SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital / Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02446, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Electric shocks + chemo: new hope for inoperable tumors?
- Could chemo before surgery beat sarcoma? new trial aims to find out
- 800-Patient study aims to tailor sarcoma treatment
- New combo therapy aims to improve sarcoma surgery outcomes
- Double dose of numbing drug may slash opioid need after sarcoma surgery
- New radiation method aims to improve sarcoma surgery outcomes